Voriconazole
Voriconazole (Vfend -- Pfizer), an antifungal triazole structurally related to fluconazole (Diflucan) with a spectrum of action similar to that of itraconazole, has been approved by the FDA for primary treatment of invasive aspergillosis and for refractory infection with Scedosporium apiospermum (the asexual form of Pseudallescheria boydii) or Fusarium spp....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Voriconazole
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1135
Article Code: 1135a
Date: July 22, 2002
Volume: 44
Pages: 63-65
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1135
Article Code: 1135a
Date: July 22, 2002
Volume: 44
Pages: 63-65
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)